Clinical Trials
29 trialsPemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Incyte Corporation
Optimus
Incyte Corporation
PRESERVE3
G1 Therapeutics, Inc.
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
National Cancer Institute (NCI)
PEGASUS
European Association of Urology Research Foundation
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Case Comprehensive Cancer Center
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
University of Washington
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
SCRI Development Innovations, LLC
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Hoosier Cancer Research Network
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Mirati Therapeutics Inc.
Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer
University of California, Irvine
ATLAS
pharmaand GmbH
Neoadjuvant Immunotherapy in Brain Metastases
Duke University
ReChiVe
Centre Hospitalier Universitaire de Saint Etienne
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
University of Michigan Rogel Cancer Center
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Weill Medical College of Cornell University
CabUC
Johannes Gutenberg University Mainz
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Latin American Cooperative Oncology Group
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Genentech, Inc.
BEZ235
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy
UNC Lineberger Comprehensive Cancer Center
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
University of Michigan
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Dendreon
iNSITE2
BIND Therapeutics
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
M.D. Anderson Cancer Center
Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract
Gustave Roussy, Cancer Campus, Grand Paris